ClinicalTrials.gg
CompletedNCT02269917Updated Dec 9, 2021Results posted

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

A Phase 3 interventional study of D/C/F/TAF and Boosted Protease Inhibitor (bPI) in Human Immunodeficiency Virus Type 1, sponsored by Janssen R&D Ireland. Completed at 82 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-09.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Janssen R&D Ireland (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1 ribonucleic acid [HIV-1 RNA] concentrations less than [\<] 50 copies per milliliter [copies/mL]) HIV-1 infected participants.

Read the detailed description

This is a randomized (study medication assigned to participants by chance), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), open-label (participants and researchers are aware about the treatment, participants are receiving), multicenter (when more than 1 hospital or medical school team work on a medical research study), study in virologically-suppressed, HIV-1 infected adult participants. The study will include a Screening Period of approximately 30 days (up to maximum 6 weeks), a controlled Treatment Period of 48 weeks, an Extension Phase of 48 weeks. All eligible participants will be randomly assigned to receive either current treatment regimen - a bPI (limited to DRV with low-dose ritonavir [rtv] or COBI, atazanavir [ATV] with rtv or COBI, or lopinavir [LPV] with rtv) combined with FTC/TDF, or experimental treatment regimen - D/C/F/TAF once-daily single-tablet for 48 weeks. After completion of week 48, participants assigned to the experimental treatment will continue with D/C/F/TAF in the extension phase up to week 96 . Participants who continued their current regimen will receive the experimental treatment (if all criteria are fulfilled) at week 52 up to week 96. As from Week 96, all participants will be given the option to continue D/C/F/TAF treatment, if they wish and if they continue to benefit from it until D/C/F/TAF becomes commercially available and is reimbursed, or can be accessed through another source in the country where he/she is living,or until the sponsor terminates clinical development. A bone investigation substudy will be performed at selected study sites, to assess bone biomarkers and energy x-ray absorptiometry (DXA) scans, in approximately 300 participants (200 in the D/C/F/TAF treatment arm versus 100 in the control arm) who provide informed consent for the substudy.

02

Conditions studied

  • Human Immunodeficiency Virus Type 1

Browse trials for

Keywords

  • Human Immunodeficiency Virus Type 1
  • Emerald
  • Darunavir
  • Cobicistat
  • Emtricitabine
  • Tenofovir Alafenamide
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 1,149 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Janssen R&D Ireland is the lead sponsor of 32 studies on the registry; none are open to participants now.

First submitted after Janssen R&D Ireland became part of Johnson & Johnson.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently being treated with a stable antiretroviral (ARV) regimen consisting of a boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) only, for at least 6 consecutive months preceding the Screening visit
  • On-treatment plasma type 1 ribonucleic acid (HIV-1 RNA) concentrations less than (\<) 50 copies per milliliter (copies/mL) or HIV-1 RNA undetectable by a local HIV-1 RNA test between 12 and 2 months prior to the Screening visit and have HIV-1 RNA \<50 copies/mL at the Screening visit
  • A single virologic elevation of greater than or equal to (>=) 50 copies/mL after previously reaching viral suppression between 12 and 2 months prior to Screening is acceptable, provided a subsequent test prior to Screening was \<50 copies/mL
  • Absence of history of failure on DRV treatment and absence of DRV resistance-associated mutations (RAMs), if documented historical genotypes are available
  • Normal (ECG) at Screening (or if abnormal, determined by the Investigator to be not )

Exclusion criteria

Exclusion Criteria:

  • A new acquired immunodeficiency syndrome (AIDS) - defining condition diagnosed within the 30 days prior to Screening
  • Proven or suspected acute hepatitis within 30 days prior to study entry
  • antibody positive; however, participants previously cured of hepatitis C virus (HCV) infection, with documented sustained virologic response, that is, undetectable HCV RNA 24 weeks after the last dose of HCV treatment, are allowed to participate
  • surface antigen (HBsAg) positive
  • Participants with cirrhosis as diagnosed based on local practices
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,149 participants (actual)

Study arms

  • Experimental
    Experimental Treatment Regimen

    Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).

    Drug: D/C/F/TAF

  • Active comparator
    Current Treatment Regimen

    Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).

    Drug: Boosted Protease Inhibitor (bPI) · Drug: FTC/TDF

Interventions

  • DrugD/C/F/TAF

    Drug page: Tenofovir alafenamide

    Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.

  • DrugBoosted Protease Inhibitor (bPI)

    Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.

  • DrugFTC/TDF

    Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48

    Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (\>=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.

    Time frame: Through Week 48

Secondary outcomes

  1. Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=20 Copies/mL) Cumulative Through 48 Weeks

    Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.

    Time frame: Through 48 Weeks

  2. Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=200 Copies/mL) Cumulative Through 48 Weeks

    Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.

    Time frame: Through 48 Weeks

  3. Percentage of Participants With Non-Virologic Rebound at Week 48 by Kaplan-Meier Estimates

    Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at week 48.

    Time frame: Baseline up to Week 48

  4. Percentage of Participants Experiencing Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Through Week 48

    An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.

    Time frame: Up to Week 48

  5. Change From Baseline in Serum Creatinine Levels at Weeks 24 and 48

    Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed.

    Time frame: Baseline and Weeks 24 and 48

  6. Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Weeks 24 and 48

    Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min).

    Time frame: Baseline, Weeks 24 and 48

  7. Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48

    Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993age.

    Time frame: Baseline, Weeks 24 and 48

  8. Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48

    Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996age (\*0.932 if female).

    Time frame: Baseline, Weeks 24 and 48

  9. Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) and Urine Protein to Creatinine Ratio (UPCR) at Weeks 24 and 48

    Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function.

    Time frame: Baseline, Weeks 24 and 48

  10. Change From Baseline in Urine Retinol Binding Protein to Creatinine Ratio (URBPCR) and Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Weeks 24 and 48

    Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function.

    Time frame: Baseline, Weeks 24 and 48

  11. Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Weeks 24 and 48

    Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  12. Percentage of Participants With Virologic Response Based on HIV-1 RNA Less Than (<)20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Food and Drug Administration (FDA) Snapshot Approach

    Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA \<20/50/200 copies/mL (observed case).

    Time frame: Week 48

  13. Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm

    Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.

    Time frame: Week 48

  14. Change From Baseline in Cluster of Differentiation 4 Plus (CD4+) Cell Count at Weeks 24 and 48

    Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  15. Percentage of Participants With Treatment Adherence of Greater Than (>)95 Percent (%) (Approach 1) Through Week 48

    Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1).

    Time frame: Through Week 48

  16. Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 48

    Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2).

    Time frame: Through Week 48

  17. Number of Participants With Resistance to Study Drug

    HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value \>=400 copies/mL or who discontinued with last HIV-1 RNA \>=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined.

    Time frame: Up to Week 48

  18. Predose (Trough) Plasma Concentration (C0h) of Darunavir

    Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis.

    Time frame: Predose at Weeks 2, 4, 8, 12, 24, 36, and 48

  19. Percent Change From Baseline in Serum Procollagen 1 N-Terminal Propeptide (P1NP) and Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) Levels at Weeks 24 and 48

    Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  20. Percent Change From Baseline in Parathyroid Hormone (PTH) at Weeks 24 and 48

    Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  21. Percent Change From Baseline in 25-hydroxy Vitamin D at Weeks 24 and 48

    Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  22. Percent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24 and 48

    Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48.

    Time frame: Baseline, Weeks 24 and 48

  23. Change From Baseline in Bone Mineral Density (BMD) T-Score at Weeks 24 and 48

    Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values \>= -1.0 were considered normal, T-score values \< -1.0 to -2.5 indicate osteopenia and T-score values \< -2.5 indicate osteoporosis.

    Time frame: Baseline, Weeks 24 and 48

  24. Percentage of Participants With Virologic Rebound (HIV-1 RNA >=20 Copies/mL) Cumulative Through Week 96

    Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.

    Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  25. Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 96

    Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=50 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=50copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.

    Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  26. Percentage of Participants With Virologic Rebound (HIV-1 RNA >=200 Copies/mL) Cumulative Through Week 96

    Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=200 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=200 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.

    Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  27. Percentage of Participants With Non-Virologic Rebound at Week 96 by Kaplan-Meier Estimates

    Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at Week 96.

    Time frame: Baseline to Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  28. Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach

    Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as having last available HIV-1 RNA \<20/50/200 copies/mL (observed case).

    Time frame: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])

  29. Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the TLOVR Algorithm

    Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.

    Time frame: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])

  30. Percentage of Participants With Virologic Failure Based on HIV-1 RNA >=20, >=50, and >=200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach

    Percentage of participants with virologic failure based on HIV-1 RNA \>=20, \>=50, and \>=200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic failure was defined by the FDA snapshot approach as having last available HIV-1 RNA \>=20/50/200 copies/mL at Week 96; virologic failure - leading to discontinuation; virologic failure - discontinued due to other reason and last available HIV-1 RNA \>=20/50/200 copies/mL.

    Time frame: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])

  31. Change From Reference in CD4+ Cell Count at Week 96

    Change from reference in CD4+ cell count was assessed at Week 96. The change from reference in CD4+ count at a given time point is defined as: CD4+ at a given time point minus reference CD4+. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF (Comprising 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52])

  32. Number of Participants With Resistance to Study Drug Through Week 96

    HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound in case they had HIV-1 RNA values \>=400 copies/mL at failure or at later time points, including participants who discontinued with last HIV-1 RNA \>=400 copies/mL. Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Number of participants who developed resistance to any of the study drug (DRV, FTC, and TFV/TAF) were reported.

    Time frame: Through Week 96 (D/C/F/TAF arm), up to Week 48 (Control arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  33. Percentage of Participants With Treatment Adherence of >95 (Approach 1) Through Week 96

    Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 96 (Approach 1).

    Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  34. Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 96

    Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 96, whichever came sooner (Approach 2).

    Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  35. Percentage of Participants Experiencing Grade 3 and Grade 4 AEs, SAEs, and Premature Discontinuation Due to AEs Through Week 96

    AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)

  36. Change From Reference in Serum Creatinine Levels at Week 96

    Change from reference in serum creatinine levels at Week 96 was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  37. Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Week 96

    Change from reference in eGFRcr (by Cockcroft-Gault formula) was assessed at Week 96. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  38. Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (by CKD-EPI) at Week 96

    Change from reference in eGFRcr (by CKD-EPI) was assessed at Week 96. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993\^age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993\^age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993\^age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993\^age. . For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  39. Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (by CKD-EPI) at Week 96

    Change from reference in eGFRcyst (by CKD-EPI) was assessed at Week 96. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996\^age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996\^age (\*0.932 if female). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  40. Change From Reference in UACR at Week 96

    Change from reference in UACR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  41. Change From Reference in URBPCR at Week 96

    Change from reference in URBPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  42. Change From Reference in UPCR at Week 96

    Change from reference in UPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  43. Change From Reference in UB2MGCR at Week 96

    Change from reference in UB2MGCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  44. Percent Change From Reference in FEPO4 at Week 96

    Percent change from reference in FEPO4 at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  45. Percent Change From Reference in Levels of Serum P1NP at Week 96

    Percent change from reference in serum P1NP levels at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  46. Percent Change From Reference in Levels of Serum CTX at Week 96

    Percent change from reference in serum CTX at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  47. Percent Change From Reference in Levels of PTH at Week 96

    Percent change from reference in PTH at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  48. Percent Change From Reference in Levels of 25-OH Vitamin D at Week 96

    Percent change from reference in 25-OH Vitamin D at Week 96 were reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  49. Percent Change From Reference in Hip and Spine BMD at Week 96

    The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  50. Change From Reference in BMD T-score of Hip and Spine at Week 96

    BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

    Time frame: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF

  51. Percentage of Participants With Non-Virologic Rebound by Kaplan-Meier Estimates

    Virologic rebound is defined as participants who show confirmed HIV-1 RNA \>=50 copies/mL, or for which the last available (single) HIV-1 RNA value on treatment was \>=50 copies/mL. Here, Kaplan-Meier estimates (%) of non-virologic rebound at every 6 months interval are presented.

    Time frame: Week 96 to end of extension (at every 6 months, up to 42 months)

  52. Percentage of Participants With Non-Treatment Failure by Kaplan-Meier Estimates

    Percentage of participants with non-treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic rebound or having discontinued for reasons other than alternate access to D/C/F/TAF (or other antiretroviral \[ARV\]).

    Time frame: Week 96 to end of extension (up to 42 months)

  53. Percentage of Participants With HIV RNA <50, <20, <200 Copies/mL Post Week 96 to End of Extension

    Percentage of participants with HIV RNA \<50, \<20, \<200 copies/mL post Week 96 to end of extension were reported.

    Time frame: Week 96 to end of extension (up to 42 months)

  54. CD4+ Cell Count Post-Week 96 to End of Extension

    The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.

    Time frame: Week 96 to end of extension (up to 42 months)

  55. Percentage of Participants With Treatment Adherence of >95% From Week 96 to End of Extension

    Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability and was calculated cumulative from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study from Week 96 to end of extension.

    Time frame: Week 96 to end of extension (up to 42 months)

  56. Percentage of Participants Experiencing Grade 3 and 4 AEs, Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Post-Week 96 to End of Extension

    AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From Week 96 to end of extension (up to 42 months)

07

Results

Posted Nov 9, 2018
Limitations and caveats
The limitation of the study was the open-label design.

Participant flow

BL to EOE-Test and BL to Switch-Control
Participant flow — BL to EOE-Test and BL to Switch-Control
MilestoneD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Switch to D/C/F/TAF
Started7663830
Treated7633780
Completed6493520
Not completed117310
Withdrew: Lost to follow-up2570
Withdrew: Other1940
Withdrew: Withdrawal by subject32100
Withdrew: Adverse event2440
Withdrew: Non-compliance with study drug400
Withdrew: Physician decision400
Withdrew: Protocol violation210
Withdrew: Death400
Withdrew: Randomized but not treated350
Switch to D/C/F/TAF (Until EOE)
Participant flow — Switch to D/C/F/TAF (Until EOE)
MilestoneD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Switch to D/C/F/TAF
Started00352
Completed00314
Not completed0038
Withdrew: Death001
Withdrew: Lost to follow-up0010
Withdrew: Adverse event0011
Withdrew: Physician decision001
Withdrew: Pregnancy002
Withdrew: Withdrawal by subject005
Withdrew: Other008

Outcome measures

PrimaryPercentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48

Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (\>=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.

Time frame:
Through Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48
Percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 482.5 (1.5 to 3.9)2.1 (0.9 to 4.1)
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Stratum-adjusted Mantel-Haenszel (MH) · p = <0.001 · Difference in percentage: 0.4 · 95% CI -1.5 to 2.2
SecondaryPercentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=20 Copies/mL) Cumulative Through 48 Weeks

Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.

Time frame:
Through 48 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=20 Copies/mL) Cumulative Through 48 Weeks
Percentage of ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=20 Copies/mL) Cumulative Through 48 Weeks10.5 (8.4 to 12.9)11.4 (8.4 to 15.0)
SecondaryPercentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=200 Copies/mL) Cumulative Through 48 Weeks

Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported.

Time frame:
Through 48 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=200 Copies/mL) Cumulative Through 48 Weeks
Percentage of ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percentage of Participants With Virologic Rebound (Plasma HIV-1 RNA >=200 Copies/mL) Cumulative Through 48 Weeks0.4 (0.1 to 1.1)0.0 (NA to NA)
SecondaryPercentage of Participants With Non-Virologic Rebound at Week 48 by Kaplan-Meier Estimates

Virologic rebound was defined as: confirmed plasma HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason). Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at week 48.

Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Non-Virologic Rebound at Week 48 by Kaplan-Meier Estimates
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percentage of Participants With Non-Virologic Rebound at Week 48 by Kaplan-Meier Estimates97.7 (96.4 to 98.6)97.8 (95.7 to 98.9)
SecondaryPercentage of Participants Experiencing Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Through Week 48

An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Through Week 48
Percentage of ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Grade 3 AEs5.66.3
Grade 4 AEs1.21.9
SAEs4.64.8
Premature discontinuations due to AEs1.41.3
SecondaryChange From Baseline in Serum Creatinine Levels at Weeks 24 and 48

Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed.

Time frame:
Baseline and Weeks 24 and 48
Reported as:
Least squares mean · micro mole per liter
Change From Baseline in Serum Creatinine Levels at Weeks 24 and 48
micro mole per literD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Change at Week 241.22 ± 0.3580.88 ± 0.509
Change at Week 481.27 ± 0.3680.65 ± 0.530
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.580 · Least square (ls) mean difference: 0.34 · 95% CI -0.88 to 1.57
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.340 · Least square (ls) mean difference: 0.62 · 95% CI -0.65 to 1.88
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Weeks 24 and 48

Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min).

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Least squares mean · milliliter per minute (mL/min)
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Weeks 24 and 48
milliliter per minute (mL/min)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Change at Week 24-0.38 ± 0.5020.20 ± 0.715
Change at Week 48-0.94 ± 0.492-0.20 ± 0.708
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.506 · Ls mean difference: -0.58 · 95% CI -2.30 to 1.13
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.392 · Ls mean difference: -0.74 · 95% CI -2.43 to 0.95
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48

Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993age.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Change at Week 24-1.67 ± 0.359-0.75 ± 0.510
Change at Week 48-1.97 ± 0.369-0.88 ± 0.531
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.143 · Ls mean difference: -0.92 · 95% CI -2.14 to 0.31
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.092 · Ls mean difference: -1.09 · 95% CI -2.36 to 0.18
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48

Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996age (\*0.932 if female).

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst, by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at Weeks 24 and 48
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
eGFRcyst: Change at Week 240.21 ± 0.338-0.93 ± 0.483
eGFRcyst: Change at Week 48-0.42 ± 0.360-1.76 ± 0.517
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.054 · Ls mean difference: 1.14 · 95% CI -0.02 to 2.29
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.034 · Ls mean difference: 1.34 · 95% CI 0.10 to 2.57
SecondaryChange From Baseline in Urine Albumin to Creatinine Ratio (UACR) and Urine Protein to Creatinine Ratio (UPCR) at Weeks 24 and 48

Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Median · milligram per gram (mg/g)
Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) and Urine Protein to Creatinine Ratio (UPCR) at Weeks 24 and 48
milligram per gram (mg/g)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
UACR: Baseline6.20 (1.4 to 632.1)7.14 (1.1 to 268.0)
UACR: Change at Week 24-0.78 (-185.4 to 422.2)0.44 (-238.5 to 145.0)
UACR: Change at Week 48-0.76 (-195.8 to 344.3)0.40 (-121.7 to 110.9)
UPCR: Baseline61.56 (16.9 to 1158.1)62.90 (14.7 to 870.9)
UPCR: Change at Week 24-14.63 (-509.6 to 734.6)0.07 (-359.9 to 400.8)
UPCR: Change at Week 48-22.25 (-520.1 to 386.6)-7.37 (-368.7 to 432.3)
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
SecondaryChange From Baseline in Urine Retinol Binding Protein to Creatinine Ratio (URBPCR) and Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Weeks 24 and 48

Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Median · microgram per gram (mcg/g)
Change From Baseline in Urine Retinol Binding Protein to Creatinine Ratio (URBPCR) and Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Weeks 24 and 48
microgram per gram (mcg/g)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
URBPCR: Baseline126.19 (20.3 to 116216.2)137.16 (12.9 to 73958.4)
URBPCR: Change at Week 24-30.27 (-69873.2 to 2004.4)7.76 (-6040.1 to 60740.4)
URBPCR: Change at Week 48-27.09 (-67540.0 to 1764.3)19.66 (-5778.3 to 65203.3)
UB2MGCR: Baseline156.85 (3.8 to 91216.2)172.25 (9.8 to 92740.1)
UB2MGCR: Change at Week 24-72.64 (-72264.6 to 13536.2)12.08 (-20084.8 to 58357.6)
UB2MGCR: Change at Week 48-67.02 (-72323.4 to 21190.2)20.24 (-22173.5 to 135576.9)
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = <0.001
SecondaryPercent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Weeks 24 and 48

Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Median · Percent change
Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Weeks 24 and 48
Percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percent change at Week 243.58 (-89.4 to 1940.4)8.55 (-78.5 to 281.8)
Percent change at Week 488.42 (-97.9 to 1430.3)8.57 (-76.3 to 452.7)
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = =0.288
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · Van Elteren Test · p = =0.148
SecondaryPercentage of Participants With Virologic Response Based on HIV-1 RNA Less Than (<)20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Food and Drug Administration (FDA) Snapshot Approach

Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA \<20/50/200 copies/mL (observed case).

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Virologic Response Based on HIV-1 RNA Less Than (<)20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Food and Drug Administration (FDA) Snapshot Approach
Percentage of ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
<20 copies/mL89.8 (87.4 to 91.8)88.4 (84.7 to 91.4)
<50 copies/mL94.9 (93.1 to 96.3)93.7 (90.7 to 95.9)
<200 copies/mL95.0 (93.2 to 96.5)94.2 (91.3 to 96.3)
SecondaryPercentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm

Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 48 as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Percentage of ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
<20 copies/mL86.0 (83.3 to 88.4)83.6 (79.5 to 87.2)
<50 copies/mL93.7 (91.7 to 95.3)92.9 (89.8 to 95.2)
<200 copies/mL95.4 (93.7 to 96.8)94.7 (91.9 to 96.7)
SecondaryChange From Baseline in Cluster of Differentiation 4 Plus (CD4+) Cell Count at Weeks 24 and 48

Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · Cells per cubic millimeter (cells/mm^3)
Change From Baseline in Cluster of Differentiation 4 Plus (CD4+) Cell Count at Weeks 24 and 48
Cells per cubic millimeter (cells/mm^3)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Baseline653.3 ± 9.12641.7 ± 13.15
Change at Week 2414.3 ± 5.998.5 ± 7.76
Change at Week 4821.0 ± 5.979.1 ± 8.41
SecondaryPercentage of Participants With Treatment Adherence of Greater Than (>)95 Percent (%) (Approach 1) Through Week 48

Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1).

Time frame:
Through Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment Adherence of Greater Than (>)95 Percent (%) (Approach 1) Through Week 48
Percentage of ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percentage of Participants With Treatment Adherence of Greater Than (>)95 Percent (%) (Approach 1) Through Week 4891.685.3
SecondaryPercentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 48

Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2).

Time frame:
Through Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 48
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 4882.777.2
SecondaryNumber of Participants With Resistance to Study Drug

HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA \>=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value \>=400 copies/mL or who discontinued with last HIV-1 RNA \>=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Resistance to Study Drug
ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Number of Participants With Resistance to Study Drug13
SecondaryPredose (Trough) Plasma Concentration (C0h) of Darunavir

Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis.

Time frame:
Predose at Weeks 2, 4, 8, 12, 24, 36, and 48
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Predose (Trough) Plasma Concentration (C0h) of Darunavir
Nanogram per milliliter (ng/mL)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])
Week 21775.29 ± 1698.84
Week 41732.00 ± 1389.44
Week 81910.30 ± 1501.94
Week 121643.38 ± 1328.41
Week 242022.99 ± 1965.64
Week 361806.37 ± 1669.43
Week 481899.79 ± 1833.09
SecondaryPercent Change From Baseline in Serum Procollagen 1 N-Terminal Propeptide (P1NP) and Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) Levels at Weeks 24 and 48

Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · Percent Change
Percent Change From Baseline in Serum Procollagen 1 N-Terminal Propeptide (P1NP) and Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) Levels at Weeks 24 and 48
Percent ChangeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
P1NP: Percent change at Week 24-22.971 ± 1.8818-0.027 ± 2.7325
P1NP: Percent change at Week 48-26.752 ± 1.8960-3.751 ± 2.6988
CTX: Percent change at Week 24-16.772 ± 2.257516.312 ± 3.8855
CTX: Percent change at Week 48-10.517 ± 3.23255.433 ± 4.1118
SecondaryPercent Change From Baseline in Parathyroid Hormone (PTH) at Weeks 24 and 48

Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · Percent change
Percent Change From Baseline in Parathyroid Hormone (PTH) at Weeks 24 and 48
Percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percent change at Week 24-3.092 ± 2.594112.034 ± 4.1777
Percent change at Week 48-4.510 ± 2.53759.436 ± 4.4784
SecondaryPercent Change From Baseline in 25-hydroxy Vitamin D at Weeks 24 and 48

Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · Percent change
Percent Change From Baseline in 25-hydroxy Vitamin D at Weeks 24 and 48
Percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Percent change at Week 24-3.0 ± 5.064.2 ± 6.13
Percent change at Week 4825.2 ± 5.5124.9 ± 7.46
SecondaryPercent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24 and 48

Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24 and 48
Percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Spine BMD: Percent change at Week 241.55 ± 0.2760.18 ± 0.342
Spine BMD: Percent change at Week 482.06 ± 0.3240.01 ± 0.391
Hip BMD: Percent change at Week 240.91 ± 0.2300.00 ± 0.279
Hip BMD: Percent change at Week 481.62 ± 0.244-0.08 ± 0.288
Statistical analysis
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = <0.001 · Ls mean difference: 1.37 · 95% CI 0.697 to 2.037
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = <0.001 · Ls mean difference: 2.05 · 95% CI 1.277 to 2.814
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = =0.001 · Ls mean difference: 0.90 · 95% CI 0.366 to 1.436
  • D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) vs Control (Baseline to Switch) · ANCOVA · p = <0.001 · Ls mean difference: 1.70 · 95% CI 1.144 to 2.248
SecondaryChange From Baseline in Bone Mineral Density (BMD) T-Score at Weeks 24 and 48

Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values \>= -1.0 were considered normal, T-score values \< -1.0 to -2.5 indicate osteopenia and T-score values \< -2.5 indicate osteoporosis.

Time frame:
Baseline, Weeks 24 and 48
Reported as:
Mean · Units on a scale
Change From Baseline in Bone Mineral Density (BMD) T-Score at Weeks 24 and 48
Units on a scaleD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)
Spine BMD T-score: Baseline-0.713 ± 0.0850-0.467 ± 0.1260
Spine BMD T-score: Change at Week 240.102 ± 0.0172-0.033 ± 0.0253
Spine BMD T-score: Change at Week 480.132 ± 0.0217-0.063 ± 0.0264
Hip BMD T-score: Baseline-0.575 ± 0.0643-0.484 ± 0.0839
Hip BMD T-score: Change at Week 240.037 ± 0.0108-0.024 ± 0.0144
Hip BMD T-score: Change at Week 480.095 ± 0.0122-0.016 ± 0.0139
Femoral Neck BMD T-score: Baseline-0.782 ± 0.0625-0.699 ± 0.0899
Femoral Neck BMD T-score: Change at Week 240.019 ± 0.0128-0.044 ± 0.0183
Femoral Neck BMD T-score: Change at Week 480.039 ± 0.0146-0.039 ± 0.0214
SecondaryPercentage of Participants With Virologic Rebound (HIV-1 RNA >=20 Copies/mL) Cumulative Through Week 96

Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.

Time frame:
Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=20 Copies/mL) Cumulative Through Week 96
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=20 Copies/mL) Cumulative Through Week 9613.8 (11.4 to 16.4)8.8 (6.1 to 12.3)
SecondaryPercentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 96

Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=50 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=50 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=50copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.

Time frame:
Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 96
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 963.1 (2.0 to 4.6)2.3 (1.0 to 4.4)
SecondaryPercentage of Participants With Virologic Rebound (HIV-1 RNA >=200 Copies/mL) Cumulative Through Week 96

Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=200 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=200 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=200 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported.

Time frame:
Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=200 Copies/mL) Cumulative Through Week 96
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=200 Copies/mL) Cumulative Through Week 960.5 (0.1 to 1.3)0.6 (0.1 to 2.0)
SecondaryPercentage of Participants With Non-Virologic Rebound at Week 96 by Kaplan-Meier Estimates

Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at Week 96.

Time frame:
Baseline to Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-Virologic Rebound at Week 96 by Kaplan-Meier Estimates
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With Non-Virologic Rebound at Week 96 by Kaplan-Meier Estimates96.7 (95.1 to 97.8)97.8 (95.4 to 98.9)
SecondaryPercentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach

Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as having last available HIV-1 RNA \<20/50/200 copies/mL (observed case).

Time frame:
Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
<20 copies/mL85.3 (82.6 to 87.8)89.8 (86.1 to 92.7)
<50 copies/mL90.7 (88.4 to 92.7)93.8 (90.7 to 96)
<200 copies/mL91.2 (89.0 to 93.1)95.5 (92.7 to 97.4)
SecondaryPercentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the TLOVR Algorithm

Percentage of participants with virologic response based on HIV-1 RNA \<20, \<50, and \<200 copies/mL threshold were analyzed at Week 96 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA \<20/50/200 copies/mL.

Time frame:
Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Response Based on HIV-1 RNA <20, <50, and <200 Copies/mL Threshold at Week 96 as Defined by the TLOVR Algorithm
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
<20 copies/mL79.6 (76.5 to 82.4)88.1 (84.2 to 91.3)
<50 copies/mL89.6 (87.3 to 91.7)94.3 (91.4 to 96.5)
<200 copies/mL91.7 (89.6 to 93.6)95.7 (93.1 to 97.6)
SecondaryPercentage of Participants With Virologic Failure Based on HIV-1 RNA >=20, >=50, and >=200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach

Percentage of participants with virologic failure based on HIV-1 RNA \>=20, \>=50, and \>=200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic failure was defined by the FDA snapshot approach as having last available HIV-1 RNA \>=20/50/200 copies/mL at Week 96; virologic failure - leading to discontinuation; virologic failure - discontinued due to other reason and last available HIV-1 RNA \>=20/50/200 copies/mL.

Time frame:
Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure Based on HIV-1 RNA >=20, >=50, and >=200 Copies/mL Threshold at Week 96 as Defined by the FDA Snapshot Approach
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
>=20 copies/mL6.8 (5.1 to 8.8)6.0 (3.7 to 9.0)
>=50 copies/mL1.2 (0.5 to 2.2)1.7 (0.6 to 3.7)
>=200 copies/mL0.3 (0.0 to 0.9)0 (NA to NA)
SecondaryChange From Reference in CD4+ Cell Count at Week 96

Change from reference in CD4+ cell count was assessed at Week 96. The change from reference in CD4+ count at a given time point is defined as: CD4+ at a given time point minus reference CD4+. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF (Comprising 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52])
Reported as:
Least squares mean · cells per cubic millimeter (cells/mm^3)
Change From Reference in CD4+ Cell Count at Week 96
cells per cubic millimeter (cells/mm^3)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in CD4+ Cell Count at Week 9632.07 ± 8.013.07 ± 10.7
SecondaryNumber of Participants With Resistance to Study Drug Through Week 96

HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound in case they had HIV-1 RNA values \>=400 copies/mL at failure or at later time points, including participants who discontinued with last HIV-1 RNA \>=400 copies/mL. Virologic rebound was defined as: confirmed plasma HIV-1 RNA level \>=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA \>=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA \>=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load \[re\]test having occurred no later than 6 weeks after Week 96). Number of participants who developed resistance to any of the study drug (DRV, FTC, and TFV/TAF) were reported.

Time frame:
Through Week 96 (D/C/F/TAF arm), up to Week 48 (Control arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Count of participants · Participants
Number of Participants With Resistance to Study Drug Through Week 96
ParticipantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Switch to D/C/F/TAF
DRV resistance-associated mutations (RAMs)000
TFV RAMs000
FTC RAMs001
SecondaryPercentage of Participants With Treatment Adherence of >95 (Approach 1) Through Week 96

Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative through Week 96 (Approach 1).

Time frame:
Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Adherence of >95 (Approach 1) Through Week 96
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With Treatment Adherence of >95 (Approach 1) Through Week 9691.687.3
SecondaryPercentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 96

Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 96, whichever came sooner (Approach 2).

Time frame:
Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 96
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With Treatment Adherence of >95% (Approach 2) Through Week 9682.880.9
SecondaryPercentage of Participants Experiencing Grade 3 and Grade 4 AEs, SAEs, and Premature Discontinuation Due to AEs Through Week 96

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Grade 3 and Grade 4 AEs, SAEs, and Premature Discontinuation Due to AEs Through Week 96
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Grade 3 AEs10.56.3
Grade 4 AEs2.41.1
SAEs8.76.0
Premature discontinuations due to AEs2.22.0
SecondaryChange From Reference in Serum Creatinine Levels at Week 96

Change from reference in serum creatinine levels at Week 96 was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · micro mole per liter
Change From Reference in Serum Creatinine Levels at Week 96
micro mole per literD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Serum Creatinine Levels at Week 960.0 (-35 to 44)0.0 (-45 to 29)
SecondaryChange From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Week 96

Change from reference in eGFRcr (by Cockcroft-Gault formula) was assessed at Week 96. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)\*(weight in kilogram \[kg\])/72\*(serum creatinine in milligram per deciliter \[mg/dL\])=eGFRcr (milliliter per minute \[mL/min\]); Female: (140 - age in years)\*(weight in kg)/72\*(serum creatinine in mg/dL)\*0.85=eGFRcr (mL/min). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · milliliter per minute (mL/min)
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Week 96
milliliter per minute (mL/min)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr, by Cockcroft-Gault Formula [eGFRcg]) at Week 96-0.9 (-65 to 58)0.0 (-44 to 157)
SecondaryChange From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (by CKD-EPI) at Week 96

Change from reference in eGFRcr (by CKD-EPI) was assessed at Week 96. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (\<=)0.7 mg/dL: 144\*(Scr/0.7)\^-0.329\*0.993\^age; 2) Scr greater than (\>)0.7 mg/dL: 144\*(Scr/0.7)\^-1.209\*0.993\^age. Male: 1) Scr \<=0.9 mg/dL: 141\*(Scr/0.9)\^-0.411\*0.993\^age; 2) Scr \>0.9 mg/dL: 141\*(Scr/0.9)\^-1.209\*0.993\^age. . For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mL/min/1.73 m^2
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (by CKD-EPI) at Week 96
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Creatinine (by CKD-EPI) at Week 96-1.3 (-37 to 35)-0.7 (-31 to 49)
SecondaryChange From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (by CKD-EPI) at Week 96

Change from reference in eGFRcyst (by CKD-EPI) was assessed at Week 96. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) \<=0.8 mg/L: 133\*(Scyst/0.8)\^-0.499\*0.996\^age (\*0.932 if female); 2) Scyst \>0.8 mg/L: 133\*(Scyst/0.8)\^-1.328\*0.996\^age (\*0.932 if female). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · mL/min/1.73 m^2
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (by CKD-EPI) at Week 96
mL/min/1.73 m^2D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (by CKD-EPI) at Week 96-0.9 (-42 to 30)1.0 (-30 to 105)
SecondaryChange From Reference in UACR at Week 96

Change from reference in UACR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · milligram per gram (mg/g)
Change From Reference in UACR at Week 96
milligram per gram (mg/g)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in UACR at Week 96-0.63 (-209.3 to 2019.7)-0.93 (-234.6 to 13230.9)
SecondaryChange From Reference in URBPCR at Week 96

Change from reference in URBPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · microgram per gram (mcg/g)
Change From Reference in URBPCR at Week 96
microgram per gram (mcg/g)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in URBPCR at Week 96-25.08 (-61980.5 to 1393.0)-39.07 (-82240.7 to 869.9)
SecondaryChange From Reference in UPCR at Week 96

Change from reference in UPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · milligram per gram (mg/g)
Change From Reference in UPCR at Week 96
milligram per gram (mg/g)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in UPCR at Week 96-22.23 (-533.3 to 2314.7)-12.81 (-722.1 to 453.1)
SecondaryChange From Reference in UB2MGCR at Week 96

Change from reference in UB2MGCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · microgram per gram (mcg/g)
Change From Reference in UB2MGCR at Week 96
microgram per gram (mcg/g)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Change From Reference in UB2MGCR at Week 96-68.22 (-71549.3 to 7433.1)-110.31 (-152500.2 to 12288.4)
SecondaryPercent Change From Reference in FEPO4 at Week 96

Percent change from reference in FEPO4 at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Median · percent change
Percent Change From Reference in FEPO4 at Week 96
percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percent Change From Reference in FEPO4 at Week 964.15 (-88.0 to 524.8)-3.19 (-77.9 to 547.8)
SecondaryPercent Change From Reference in Levels of Serum P1NP at Week 96

Percent change from reference in serum P1NP levels at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · percent change
Percent Change From Reference in Levels of Serum P1NP at Week 96
percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percent Change From Reference in Levels of Serum P1NP at Week 96-19.899 ± 2.2151-18.466 ± 3.1169
SecondaryPercent Change From Reference in Levels of Serum CTX at Week 96

Percent change from reference in serum CTX at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · percent change
Percent Change From Reference in Levels of Serum CTX at Week 96
percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percent Change From Reference in Levels of Serum CTX at Week 96-10.192 ± 3.0592-21.755 ± 3.4926
SecondaryPercent Change From Reference in Levels of PTH at Week 96

Percent change from reference in PTH at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · percent change
Percent Change From Reference in Levels of PTH at Week 96
percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percent Change From Reference in Levels of PTH at Week 96-17.171 ± 2.6774-20.466 ± 3.2559
SecondaryPercent Change From Reference in Levels of 25-OH Vitamin D at Week 96

Percent change from reference in 25-OH Vitamin D at Week 96 were reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · percent change
Percent Change From Reference in Levels of 25-OH Vitamin D at Week 96
percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percent Change From Reference in Levels of 25-OH Vitamin D at Week 9624.6 ± 5.16-1.9 ± 3.33
SecondaryPercent Change From Reference in Hip and Spine BMD at Week 96

The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DXA scan. Positive values are "best values" and negative values are "worst values" of change. Percent change from reference in hip and spine BMD was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · percent change
Percent Change From Reference in Hip and Spine BMD at Week 96
percent changeD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Hip region BMD-T score0.0173 ± 0.002170.0108 ± 0.00328
Spine region BMD-T score0.0193 ± 0.002860.0279 ± 0.00381
SecondaryChange From Reference in BMD T-score of Hip and Spine at Week 96

BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score \>= -1, osteopenia by a T-score \>= -2.5 to \<-1.0, and osteoporosis by a T-score \<-2.5. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2).

Time frame:
From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
Reported as:
Mean · units on a scale
Change From Reference in BMD T-score of Hip and Spine at Week 96
units on a scaleD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Hip region BMD0.122 ± 0.01540.077 ± 0.0230
Spine region BMD0.176 ± 0.02590.255 ± 0.0339
SecondaryPercentage of Participants With Non-Virologic Rebound by Kaplan-Meier Estimates

Virologic rebound is defined as participants who show confirmed HIV-1 RNA \>=50 copies/mL, or for which the last available (single) HIV-1 RNA value on treatment was \>=50 copies/mL. Here, Kaplan-Meier estimates (%) of non-virologic rebound at every 6 months interval are presented.

Time frame:
Week 96 to end of extension (at every 6 months, up to 42 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-Virologic Rebound by Kaplan-Meier Estimates
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Week 96100 (100 to 100)100 (100 to 100)
Week 96 + 6 months99.4 (98.4 to 99.8)100 (100 to 100)
Week 96 + 12 months98.0 (96.5 to 98.9)98.5 (96.0 to 99.4)
Week 96 + 18 months97.6 (95.9 to 98.6)98.1 (95.4 to 99.2)
Week 96 + 24 months97.1 (94.9 to 98.3)96.5 (92.3 to 98.4)
Week 96 + 30 months95.3 (91.3 to 97.5)96.5 (92.3 to 98.4)
Week 96 + 36 months92.4 (83 to 96.7)96.5 (92.3 to 98.4)
Week 96 + 42 months92.4 (83.0 to 96.7)—
SecondaryPercentage of Participants With Non-Treatment Failure by Kaplan-Meier Estimates

Percentage of participants with non-treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic rebound or having discontinued for reasons other than alternate access to D/C/F/TAF (or other antiretroviral \[ARV\]).

Time frame:
Week 96 to end of extension (up to 42 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-Treatment Failure by Kaplan-Meier Estimates
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Week 96100 (100 to 100)100 (100 to 100)
Week 96 + 6 months98.1 (96.7 to 98.9)98.5 (96.3 to 99.4)
Week 96 + 12 months94.3 (92.2 to 95.9)95.4 (92.3 to 97.2)
Week 96 + 18 months91.6 (89.0 to 93.6)92.2 (88.3 to 94.8)
Week 96 + 24 months89.4 (86.1 to 91.9)89.7 (85.0 to 93.0)
Week 96 + 30 months87.0 (82.7 to 90.4)88.1 (82.0 to 92.2)
Week 96 + 36 months84.9 (78.2 to 89.6)82.6 (67.4 to 91.1)
Week 96 + 42 months81.7 (71.9 to 88.4)—
SecondaryPercentage of Participants With HIV RNA <50, <20, <200 Copies/mL Post Week 96 to End of Extension

Percentage of participants with HIV RNA \<50, \<20, \<200 copies/mL post Week 96 to end of extension were reported.

Time frame:
Week 96 to end of extension (up to 42 months)
Reported as:
Number · percentage of participants
Percentage of Participants With HIV RNA <50, <20, <200 Copies/mL Post Week 96 to End of Extension
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Week 96 + 6 months (<50 copies/mL)97.8 (96.4 to 98.8)97.9 (95.7 to 99.2)
Week 96 + 12 months (<50 copies/mL)98.4 (97.0 to 99.2)97.4 (94.8 to 98.8)
Week 96 + 18 months (<50 copies/mL)99.6 (98.4 to 99.9)98.7 (96.2 to 99.7)
Week 96 + 24 months (<50 copies/mL)99.3 (97.4 to 99.9)98.5 (94.7 to 99.8)
Week 96 + 30 months (<50 copies/mL)99.3 (95.9 to 100)100 (94.4 to 100)
Week 96 + 36 months (<50 copies/mL)98.1 (89.7 to 100)100 (86.8 to 100)
Week 96 + 42 months (<50 copies/mL)100 (79.4 to 100)100 (59.0 to 100)
Week 96 + 6 months (<200 copies/mL)99.1 (98.1 to 99.7)99.7 (98.3 to 100)
Week 96 + 12 months (<200 copies/mL)99.3 (98.3 to 99.8)98.7 (96.6 to 99.6)
Week 96 + 18 months (<200 copies/mL)100 (99.2 to 100)99.1 (96.8 to 99.9)
Week 96 + 24 months (<200 copies/mL)99.6 (98.0 to 100)99.3 (95.9 to 100)
Week 96 + 30 months (<200 copies/mL)100 (97.3 to 100)100 (94.4 to 100)
Week 96 + 36 months (<200 copies/mL)100 (93.2 to 100)100 (86.8 to 100)
Week 96 + 42 months (<200 copies/mL)100 (79.4 to 100)100 (59 to 100)
Week 96 + 6 months (<20 copies/mL)91.4 (89.1 to 93.4)93.4 (90.2 to 95.8)
Week 96 + 12 months (<20 copies/mL)93.9 (91.7 to 95.7)91.4 (87.6 to 94.3)
Week 96 + 18 months (<20 copies/mL)96.1 (93.9 to 97.7)92.9 (88.7 to 95.9)
Week 96 + 24 months (<20 copies/mL)96.1 (93.1 to 98.0)95.5 (90.5 to 98.3)
Week 96 + 30 months (<20 copies/mL)95.6 (90.6 to 98.4)92.2 (82.7 to 97.4)
Week 96 + 36 months (<20 copies/mL)94.2 (84.1 to 98.8)96.2 (80.4 to 99.9)
Week 96 + 42 months (<20 copies/mL)93.8 (69.8 to 99.8)100 (59 to 100)
SecondaryCD4+ Cell Count Post-Week 96 to End of Extension

The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed.

Time frame:
Week 96 to end of extension (up to 42 months)
Reported as:
Mean · cells/mm^3
CD4+ Cell Count Post-Week 96 to End of Extension
cells/mm^3D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Week 96 + 6 months706.4 ± 10.51681.3 ± 14.99
Week 96 + 12 months707.6 ± 11.93676.2 ± 14.57
Week 96 + 18 months713.3 ± 12.16686.1 ± 17.05
Week 96 + 24 months712.7 ± 15.98686.4 ± 21.20
Week 96 + 30 months730.4 ± 23.24685.8 ± 28.61
Week 96 + 36 months732.0 ± 33.10733.3 ± 54.73
Week 96 + 42 months714.3 ± 56.26705.6 ± 112.99
SecondaryPercentage of Participants With Treatment Adherence of >95% From Week 96 to End of Extension

Treatment adherence (defined as adherence of \>95%) was assessed by the drug accountability and was calculated cumulative from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study from Week 96 to end of extension.

Time frame:
Week 96 to end of extension (up to 42 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Adherence of >95% From Week 96 to End of Extension
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Percentage of Participants With Treatment Adherence of >95% From Week 96 to End of Extension89.589.4
SecondaryPercentage of Participants Experiencing Grade 3 and 4 AEs, Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Post-Week 96 to End of Extension

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From Week 96 to end of extension (up to 42 months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Grade 3 and 4 AEs, Serious Adverse Events (SAEs), and Premature Discontinuation Due to AEs Post-Week 96 to End of Extension
percentage of participantsD/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Switch to D/C/F/TAF
Grade 3 AEs5.75.0
Grade 4 AEs2.11.5
SAEs7.37.7
Premature discontinuations due to AEs1.12.1

Adverse events

Collected over Up to 5 years and 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
D/C/F/TAF (Test) (Baseline to End of Extension [EOE])4/763 (0.5%)114/763 (14.9%)584/763 (76.5%)
Control (Baseline to Switch)0/378 (0%)18/378 (4.8%)222/378 (58.7%)
Switch to D/C/F/TAF Group1/352 (0.3%)42/352 (11.9%)213/352 (60.5%)
Most frequent serious events
Showing 10 of 181
Most frequent serious events
EventD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Control (Baseline to Switch)Switch to D/C/F/TAF Group
PneumoniaInfections and infestations10/7630/3783/352
AppendicitisInfections and infestations2/7630/3783/352
DepressionPsychiatric disorders1/7630/3783/352
Suicidal ideationPsychiatric disorders1/7631/3783/352
Non-cardiac chest painGeneral disorders2/7630/3782/352
CellulitisInfections and infestations2/7631/3782/352
SepsisInfections and infestations0/7630/3782/352
Myocardial infarctionCardiac disorders4/7631/3781/352
DiverticulitisInfections and infestations4/7630/3780/352
GastroenteritisInfections and infestations4/7630/3780/352
Most frequent other events
Showing 10 of 24
Most frequent other events
EventD/C/F/TAF (Test) (Baseline to End of Extension [EOE])Control (Baseline to Switch)Switch to D/C/F/TAF Group
Upper respiratory tract infectionInfections and infestations163/76339/37856/352
NasopharyngitisInfections and infestations144/76342/37842/352
Back painMusculoskeletal and connective tissue disorders107/76323/37831/352
DiarrhoeaGastrointestinal disorders104/76318/37840/352
HeadacheNervous system disorders93/76318/37829/352
ArthralgiaMusculoskeletal and connective tissue disorders84/7639/37822/352
CoughRespiratory, thoracic and mediastinal disorders75/76317/37821/352
Vitamin D deficiencyMetabolism and nutrition disorders74/76329/37811/352
BronchitisInfections and infestations73/76310/37821/352
Abdominal painGastrointestinal disorders64/7637/3789/352

Baseline characteristics

Intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Total
Mean45.3 ± 10.8644.8 ± 10.7745.1 ± 10.83
Sex: Female, Male
Sex: Female, Male(Participants)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Total
Female14065205
Male623313936
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Total
Hispanic or Latino11159170
Not Hispanic or Latino649317966
Unknown or Not Reported325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Total
American Indian or Alaska Native527
Asian17926
Native Hawaiian or Other Pacific Islander202
Black or African American15582237
White573282855
More than one race516
Unknown or Not Reported628
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Total
Asian17926
Black or African American15582237
Hispanic or Latino9556151
Other20626
White Non-Hispanic476225701
Region of Enrollment
Region of Enrollment(Participants)D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE])Control (Baseline to Switch)Total
Belgium322052
Canada452166
France692897
Poland9135126
Spain11752169
Sweden23528
Switzerland261339
United Kingdom472370
United States313181494
08

Study locations

82 sites
  • Phoenix, Arizona, United States
  • Bakersfield, California, United States
  • Beverly Hills, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Washington, District of Columbia, United States
  • Fort Lauderdale, Florida, United States
  • Fort Pierce, Florida, United States
  • Orlando, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Savannah, Georgia, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Springfield, Massachusetts, United States
  • Berkley, Michigan, United States
  • Detroit, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Hillsborough, New Jersey, United States
  • Newark, New Jersey, United States
  • Somers Point, New Jersey, United States
  • Santa Fe, New Mexico, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Longview, Texas, United States
  • Seattle, Washington, United States
  • Antwerpen, Belgium
  • Brussels, Belgium
  • Bruxelles, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Liège, Belgium
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Le Kremlin Bicetre, France
  • Lyon, France
  • Marseille, France
  • Montpellier, France
  • Nantes, France
  • Paris Cedex 10, France
  • Paris Cedex 12, France
  • Paris, France
  • Strasbourg Cedex, France
  • Tourcoing, France
  • Bydgoszcz, Poland
  • Chorzow, Poland
  • Lodz, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • San Juan, Puerto Rico
  • Alicante, Spain
  • Badalona, Spain
  • Barcelona, Spain
  • Cordoba, Spain
  • Elche, Spain
  • Madrid, Spain
  • San Sebastian, Spain
  • Sevilla, Spain
  • Valencia, Spain
  • Göteborg, Sweden
  • Malmö, Sweden
  • Stockholm, Sweden
  • Basel, Switzerland
  • Bern, Switzerland
  • Zurich N/a, Switzerland
  • Brighton, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
09

References and documents

Publications

  • Ackaert O, McDougall D, Perez-Ruixo C, Perez-Ruixo JJ, Jezorwski J, Crauwels HM. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). AAPS J. 2021 Jun 7;23(4):82. doi: 10.1208/s12248-021-00607-8. PubMed 34100149 ↗
  • Huhn GD, Wilkin A, Mussini C, Spinner CD, Jezorwski J, El Ghazi M, Van Landuyt E, Lathouwers E, Brown K, Baugh B; AMBER and EMERALD study groups. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naive and -experienced, virologically-suppressed adults living with HIV-1. HIV Res Clin Pract. 2020 Dec;21(6):151-167. doi: 10.1080/25787489.2020.1844520. Epub 2021 Feb 2. PubMed 33528318 ↗
  • Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S; AMBER and EMERALD Study Groups. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21. PubMed 31516033 ↗
  • Huhn GD, Eron JJ, Girard PM, Orkin C, Molina JM, DeJesus E, Petrovic R, Luo D, Van Landuyt E, Lathouwers E, Nettles RE, Brown K, Wong EY. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. AIDS Res Ther. 2019 Aug 29;16(1):23. doi: 10.1186/s12981-019-0235-1. PubMed 31464642 ↗
  • Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6. PubMed 28993180 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Feb 2017, 23 months.

Results were first posted in Nov 2018, 1 year 9 months after primary completion. A results delay was requested in Feb 2018.

Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 23 months is close to that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2014
First posted
Oct 21, 2014
StartActual
Mar 2015
Primary completionActual
Feb 2017
CompletionActual
Oct 2020
Results delay requested
Feb 8, 2018
Results first posted
Nov 9, 2018
Last update
Dec 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02269917
Responsible party
Sponsor
First posted
Oct 21, 2014
Start date
Mar 2015
Primary completion
Feb 2017
Completion
Oct 2020
Results posted
Nov 9, 2018
Last update
Dec 9, 2021

Study contacts

Janssen R&D Ireland Clinical Trial
study director · Janssen R&D Ireland

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion